Kosin Med J.  2024 Mar;39(1):26-34. 10.7180/kmj.24.108.

Gastric cancer and metabolic syndrome

• Jo HH

• KMID: 2556795
• DOI: http://doi.org/10.7180/kmj.24.108

Abstract

Gastric cancer (GC), a prevalent disease in Asian countries, presents a substantial global health challenge. The risk factors for GC include Helicobacter pylori infection, diet, smoking, alcohol, and metabolic syndrome (MetS). This review meticulously examines the intricate connections between MetS and GC, focusing on visceral adipocytes, hormonal factors, obesity, and their impact on survival outcomes. Visceral adipocytes, which secrete inflammatory cytokines and hormones, play a pivotal role in influencing cancer development. Hormonal factors demonstrate nuanced associations with specific GC subtypes, underscoring the complexity of their impact. Large-scale studies exploring obesity-related factors reveal sex-specific nuances and underscore the importance of considering overall weight and body composition. Furthermore, the review explores the impact of eradication therapy for H. pylori infection, which is the most significant factor in the onset of GC, on the components of MetS. Additionally, the influence of MetS on postoperative outcomes and survival in GC patients highlights the interplay between therapeutic interventions and lifestyle factors. This comprehensive exploration sheds light on the multifaceted relationship between MetS and GC, providing valuable insights for future research and preventive strategies.

Keyword

Body mass index; Helicobacter pylori; Metabolic syndrome; Stomach neoplasms

Reference

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209–49.

2. Lee YY, Derakhshan MH. Environmental and lifestyle risk factors of gastric cancer. Arch Iran Med. 2013; 16:358–65.

3. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006; 12:354–62.

4. Tramacere I, Negri E, Pelucchi C, Bagnardi V, Rota M, Scotti L, et al. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol. 2012; 23:28–36.

5. den Hoed CM, Kuipers EJ. Gastric cancer: how can we reduce the incidence of this disease? Curr Gastroenterol Rep. 2016; 18:34.

6. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988; 37:1595–607.

7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15:539–53.

8. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640–5.

9. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014; 2014:943162.

10. Kim BY, Kang SM, Kang JH, Kang SY, Kim KK, Kim KB, et al. 2020 Korean Society for the Study of Obesity guideline for the management of obesity in Korea. J Obes Metab Syndr. 2021; 30:81–92.

11. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care. 2011; 34:1323–8.

12. Xia B, He Q, Pan Y, Gao F, Liu A, Tang Y, et al. Metabolic syndrome and risk of pancreatic cancer: a population-based prospective cohort study. Int J Cancer. 2020; 147:3384–93.

13. Johansen D, Stocks T, Jonsson H, Lindkvist B, Bjorge T, Concin H, et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev. 2010; 19:2307–17.

14. Nagel G, Bjorge T, Jaensch A, Peter RS, Haggstrom C, Lang A, et al. Metabolic factors and the risk of small intestine cancers: pooled study of 800 000 individuals in the metabolic syndrome and cancer project. Int J Cancer. 2021; 149:66–74.

15. Kim J, Park EY, Park E, Lim MK, Oh JK, Kim B. Metabolic syndrome and colorectal cancer risk: results of propensity score-based analyses in a community-based cohort study. Int J Environ Res Public Health. 2020; 17:8687.

16. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol. 2009; 15:5141–8.

17. Shin CM, Han K, Lee DH, Choi YJ, Kim N, Park YS, et al. Association among obesity, metabolic health, and the risk for colorectal cancer in the general population in Korea using the National Health Insurance Service-National Sample Cohort. Dis Colon Rectum. 2017; 60:1192–200.

18. Jin EH, Han K, Lee DH, Shin CM, Lim JH, Choi YJ, et al. Association between metabolic syndrome and the risk of colorectal cancer diagnosed before age 50 years according to tumor location. Gastroenterology. 2022; 163:637–48.

19. Choi YJ, Lee DH, Han KD, Shin CM, Kim N. Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer. Eur J Epidemiol. 2018; 33:1077–85.

20. Wani B, Aziz SA, Ganaie MA, Mir MH. Metabolic syndrome and breast cancer risk. Indian J Med Paediatr Oncol. 2017; 38:434–9.

21. Lee JA, Yoo JE, Park HS. Metabolic syndrome and incidence of breast cancer in middle-aged Korean women: a nationwide cohort study. Breast Cancer Res Treat. 2017; 162:389–93.

22. Jinjuvadia R, Patel S, Liangpunsakul S. The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol. 2014; 48:172–7.

23. Osaki Y, Taniguchi S, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol. 2012; 36:141–7.

24. Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, et al. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer. 2009; 45:1831–8.

25. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012; 35:2402–11.

26. Kim DJ, Kil SY, Son J, Lee HS. How to conduct well-designed clinical research. Kosin Med J. 2022; 37:187–91.

27. O’Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015; 16:1–12.

28. Micucci C, Valli D, Matacchione G, Catalano A. Current perspectives between metabolic syndrome and cancer. Oncotarget. 2016; 7:38959–72.

29. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2006; 207:12–22.

30. Dutta D, Ghosh S, Pandit K, Mukhopadhyay P, Chowdhury S. Leptin and cancer: pathogenesis and modulation. Indian J Endocrinol Metab. 2012; 16(Suppl 3):S596–600.

31. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4:579–91.

32. Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007; 30:561–7.

33. Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010; 59:39–48.

34. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345:784–9.

35. Kim HJ, Lim SY, Lee JS, Park S, Shin A, Choi BY, et al. Fresh and pickled vegetable consumption and gastric cancer in Japanese and Korean populations: a meta-analysis of observational studies. Cancer Sci. 2010; 101:508–16.

36. Sung NY, Choi KS, Park EC, Park K, Lee SY, Lee AK, et al. Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study. Br J Cancer. 2007; 97:700–4.

37. Chen Y, Liu L, Wang X, Wang J, Yan Z, Cheng J, et al. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Biomarkers Prev. 2013; 22:1395–408.

38. Lin XJ, Wang CP, Liu XD, Yan KK, Li S, Bao HH, et al. Body mass index and risk of gastric cancer: a meta-analysis. Jpn J Clin Oncol. 2014; 44:783–91.

39. Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer. 2003; 98:940–8.

40. Du X, Hidayat K, Shi BM. Abdominal obesity and gastroesophageal cancer risk: systematic review and meta-analysis of prospective studies. Biosci Rep. 2017; 37:BSR20160474.

41. Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control. 2005; 16:285–94.

42. Sanikini H, Biessy C, Rinaldi S, Navionis AS, Gicquiau A, Keski-Rahkonen P, et al. Circulating hormones and risk of gastric cancer by subsite in three cohort studies. Gastric Cancer. 2023; 26:969–87.

43. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965; 64:31–49.

44. Lee JY, Gong EJ, Chung EJ, Park HW, Bae SE, Kim EH, et al. The characteristics and prognosis of diffuse-type early gastric cancer diagnosed during health check-ups. Gut Liver. 2017; 11:807–12.

45. Santoro R, Carboni F, Lepiane P, Ettorre GM, Santoro E. Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg. 2007; 94:737–42.

46. Park JC, Lee YC, Kim JH, Kim YJ, Lee SK, Hyung WJ, et al. Clinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patients. J Surg Oncol. 2009; 99:395–401.

47. Jo HH, Kim N, Jang J, Choi Y, Park J, Park YM, et al. Impact of body mass index on survival depending on sex in 14,688 patients with gastric cancer in a tertiary hospital in South Korea. Gut Liver. 2023; 17:243–58.

48. Jung YJ, Kim HJ, Park CH, Park SJ, Kim N. Effects of reproductive factors on Lauren intestinal-type gastric cancers in females: a multicenter retrospective study in South Korea. Gut Liver. 2022; 16:706–15.

49. Kim SM, Min BH, Lee J, An JY, Lee JH, Sohn TS, et al. Protective effects of female reproductive factors on Lauren intestinal-type gastric adenocarcinoma. Yonsei Med J. 2018; 59:28–34.

50. Leeners B, Geary N, Tobler PN, Asarian L. Ovarian hormones and obesity. Hum Reprod Update. 2017; 23:300–21.

51. Yoo H, Kim H, Lee JH, Lee KS, Choi MJ, Song HR, et al. Study on the relevance of metabolic syndrome and incidence of gastric cancer in Korea. Int J Environ Res Public Health. 2019; 16:1101.

52. Jee SH, Yun JE, Park EJ, Cho ER, Park IS, Sull JW, et al. Body mass index and cancer risk in Korean men and women. Int J Cancer. 2008; 123:1892–6.

53. Lee HW, Huang D, Shin WK, de la Torre K, Yang JJ, Song M, et al. Obesity at early adulthood increases risk of gastric cancer from the Health Examinees-Gem (HEXA-G) study. PLoS One. 2022; 17:e0260826.

54. Lindkvist B, Almquist M, Bjorge T, Stocks T, Borena W, Johansen D, et al. Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic Syndrome and Cancer Project (Me-Can). Cancer Causes Control. 2013; 24:107–16.

55. Tian T, Zhang LQ, Ma XH, Zhou JN, Shen J. Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysis. Exp Clin Endocrinol Diabetes. 2012; 120:217–23.

56. Lin Y, Ness-Jensen E, Hveem K, Lagergren J, Lu Y. Metabolic syndrome and esophageal and gastric cancer. Cancer Causes Control. 2015; 26:1825–34.

57. Li F, Du H, Li S, Liu J. The association between metabolic syndrome and gastric cancer in Chinese. Front Oncol. 2018; 8:326.

58. Lim JH, Shin CM, Han K, Yoo J, Jin EH, Choi YJ, et al. Nationwide cohort study: cholesterol level is inversely related with the risk of gastric cancer among postmenopausal women. Gastric Cancer. 2022; 25:11–21.

59. Huang D, Shin WK, De la Torre K, Lee HW, Min S, Shin A, et al. Association between metabolic syndrome and gastric cancer risk: results from the Health Examinees Study. Gastric Cancer. 2023; 26:481–92.

60. Bae JM. Body mass index and risk of gastric cancer in Asian adults: a meta-epidemiological meta-analysis of population-based cohort studies. Cancer Res Treat. 2020; 52:369–73.

61. Liu AR, He QS, Wu WH, Du JL, Kuo ZC, Xia B, et al. Body composition and risk of gastric cancer: a population-based prospective cohort study. Cancer Med. 2021; 10:2164–74.

62. Mohammadi M. Role of obesity in the tumorigenesis of gastric cancer. Int J Prev Med. 2020; 11:148.

63. Mariani M, Sassano M, Boccia S. Metabolic syndrome and gastric cancer risk: a systematic review and meta-analysis. Eur J Cancer Prev. 2021; 30:239–50.

64. Campbell PT, Sloan M, Kreiger N. Physical activity and stomach cancer risk: the influence of intensity and timing during the lifetime. Eur J Cancer. 2007; 43:593–600.

65. Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020; 69:2113–21.

66. Yamagata H, Kiyohara Y, Nakamura S, Kubo M, Tanizaki Y, Matsumoto T, et al. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care. 2005; 28:789–94.

67. Lim SH, Kim N, Kwon JW, Kim SE, Baik GH, Lee JY, et al. Positive association between Helicobacter pylori infection and metabolic syndrome in a Korean population: a multicenter nationwide study. Dig Dis Sci. 2019; 64:2219–30.

68. Seo KI, Heo JJ, Kim SE, Park SJ, Park MI, Moon W, et al. Sex differences between Helicobacter pylori infection and cholesterol levels in an adult health checkup program. Helicobacter. 2020; 25:e12704.

69. Mokhtare M, Mirfakhraee H, Arshad M, Samadani Fard SH, Bahardoust M, Movahed A, et al. The effects of Helicobacter pylori eradication on modification of metabolic syndrome parameters in patients with functional dyspepsia. Diabetes Metab Syndr. 2017; 11 Suppl 2:S1031–5.

70. Iwai N, Okuda T, Oka K, Hara T, Inada Y, Tsuji T, et al. Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: a single-center observational study. PLoS One. 2019; 14:e0221349.

71. Watanabe J, Hamasaki M, Kotani K. The effect of Helicobacter pylori eradication on lipid levels: a meta-analysis. J Clin Med. 2021; 10:904.

72. Park J, Kim N, Kim WS, Lim SH, Choi Y, Jo HH, et al. Long-term effects of the eradication of Helicobacter pylori on metabolic parameters, depending on sex, in South Korea. Gut Liver. 2023; 17:58–68.

73. Lee JY, Park NH, Song YS, Park SM, Lee HW, Kim KH, et al. Prevalence of the metabolic syndrome and associated factors in Korean cancer survivors. Asian Pac J Cancer Prev. 2013; 14:1773–80.

74. Hu D, Peng F, Lin X, Chen G, Zhang H, Liang B, et al. Preoperative metabolic syndrome is predictive of significant gastric cancer mortality after gastrectomy: the Fujian Prospective Investigation of Cancer (FIESTA) Study. EBioMedicine. 2017; 15:73–80.

75. Zhang X, Hu D, Deng X, Lin J, Zheng X, Peng F, et al. Prediction of presurgical metabolic syndrome for gastric cancer-specific mortality is more evident in smokers: the FIESTA study. Cancer Med. 2023; 12:3419–32.